β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Open accessThe DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 55 of the 76 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to (1) impact the natural history of β-cell failure; (2) identify and characterize genetic loci for T2D; (3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; (4) develop alternative sources of β-cells for cell-based therapy; (5) focus on metabolic environment to provide indirect benefit to β-cells; (6) improve understanding of the physiology of responses to bypass surgery; and (7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.
Overview
CoChat Summary
TL;DR
This review/consensus report from an international expert meeting argues that progressive β-cell failure is central to type 2 diabetes, involving genetic/epigenetic changes and multiple stressors that lead to dysfunction, dedifferentiation, and death. It concludes existing therapies can improve β-cell function temporarily but generally do not arrest or reverse progression, with possible exception of gastric bypass, and identifies noninvasive β-cell mass measurement and stage-specific/combinatorial interventions as key research needs.
Key findings
- Over 60 genetic loci have been convincingly associated with T2D, the great majority involved in some way in β-cell biology, but these variants explain only a small proportion of total genetic risk; approximately 50% of T2D-associated SNPs introduce or remove a CpG site, suggesting genetic-epigenetic interactions.
- β-cell mass in T2D varies and overlaps with normal individuals, although current data suggest a 20–60% reduction; human β-cell mass varies three- to fivefold unrelated to age or BMI, and insulin sensitivity may vary as much as 10-fold. β-cell function and mass declines are not well correlated, while deteriorating β-cell function is tightly correlated with climbing glucose levels.
- Multiple stressors are implicated: ER stress, metabolic/oxidative stress, amyloid/IAPP oligomers, islet inflammation (IL-1β antagonism can preserve some β-cell functional mass), and disrupted islet integrity. β-cell dedifferentiation has regained favor, and residual β-cells remain even in late disease.
- Interventions show temporary β-cell functional improvement: in the DPP, greater baseline β-cell function and insulin sensitivity independently contributed to restoration of normal glucose tolerance; TZDs improved the oral disposition index; GLP-1–based therapies improve function during treatment but no meaningful persistent change follows withdrawal; RYGB produces disease remission in at least 80% of patients, with duration of diabetes and insulin use before surgery as strongest predictors.
Methods
- Design: narrative review/consensus report from the October 2013 meeting “Beta Cell Failure in Type 2 Diabetes,” cosponsored by the Endocrine Society and the American Diabetes Association, assembling international experts to review the state of the science and identify research needs.
- Data/sample: no primary experimental sample; synthesis of published human and animal studies, including genetics, epigenetics, islet biology, clinical trials, and surgical interventions.
- Analysis: expert discussion and narrative synthesis; future research goals are presented in Table 1 (not included in the provided text).
Limitations
- Stated: studies of epigenetics in T2D are severely limited by the small number of islets available from patients with T2D and by difficulty separating cause and effect in hyperglycemia; human β-cell mass measurement relies entirely on postmortem, cross-sectional assessments, and histomorphometric measurement of β-cell area, volume, and mass is often imprecisely defined and complicated by technical inconsistencies.
- Stated: no study has established whether one pathogenic pathway dominates or can serve as a single major target; durability of β-cell functional improvements following therapy withdrawal remains challenging, and whether earlier intervention can alter the natural history of β-cell failure is unknown.
- Evident from the text: as an expert consensus/narrative review, it does not describe a systematic search strategy or quantitative meta-analysis, and many cited mechanisms and genetic associations remain uncertain or require human validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
35 Valid · 6 Not valid · 7 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“At the time of writing, over 60 genetic loci have been convincingly associated with T2D”
What the sources say
- Disputedcites [8] Voight, 2010, Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis, Nat Genet sourceExperimental — accuracy not yet measured
The Discussion states that the number of confirmed T2D loci stood at 38 when the source paper was written, not over 60. The paper cannot establish a later count at the citing document’s time of writing. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [9] Rosengren, 2012, Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes, Diabetes sourceExperimental — accuracy not yet measured
The source paper's Abstract says recent genome-wide association studies had identified close to 50 loci associated with T2D risk, not over 60. Its count is contrary to the number attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
What the sources say
- Not checked — no full text of the sourcecites [71] Fehse, 2005, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab source
- Disputedcites [73] Bunck, 2011, Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Results (Measures of β-cell function; page unavailable) report a sustained improvement in the disposition index four weeks after exenatide withdrawal, contrary to the categorical claim that none of these agents produced a persistent change. The Conclusions call the effect small and note that it was not enough to sustain glycemic control; the Results (Glycemic control; page unavailable) report that HbA1c and fasting glucose returned to pretreatment values after 12 weeks off treatment. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“further suggest that hyperglycemia alters DNA methylation of PDX1 and INS ( 22 – 25 ).”
What the sources say
- Partly supportedcites [22] Yang, 2012, Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes, Mol Endocrinol sourceExperimental — accuracy not yet measured
The 'Impact of hyperglycemia on DNA methylation of PDX-1' section (page not supplied) reports that HbA1c correlated with PDX-1 methylation in human islets and that high glucose nominally increased Pdx-1 methylation in rat β-cells. The paper does not present a corresponding finding that hyperglycemia alters INS methylation; its Discussion mentions insulin-promoter methylation in patients with type 2 diabetes as a finding from earlier work. (LLM, conf=0.85)
- Supportedcites [23] Yang, 2011, Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets, Diabetologia source
The Discussion reports that 72 hours of hyperglycaemia increased insulin-promoter DNA methylation in clonal rat beta cells, supporting the INS part for which this paper is cited. PDX1 appears only as an insulin-promoter binding-site label in the Results figure caption; this paper is not the source for that part of the multi-citation sentence. (LLM, conf=0.90)
- Could not verifycites [24] Ling, 2008, Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion, Diabetologia sourceExperimental — accuracy not yet measured
The Methods and Results (page not available) examine DNA methylation of PPARGC1A and report higher methylation in diabetic than non-diabetic islets. Searches for PDX1, INS, and hyperglycemia-related methylation found no passage addressing whether hyperglycemia alters methylation of PDX1 or INS. (LLM, conf=0.74)
- Disputedcites [25] Volkmar, 2012, DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients, EMBO J sourceExperimental — accuracy not yet measured
The Results section, “Differential DNA methylation observed in T2D islets is not inducible by high glucose” (page unavailable), reports no significant methylation changes at the tested sites after high-glucose exposure and concludes that T2D-related methylation differences are probably not secondary to hyperglycaemia. It does not report a high-glucose effect on PDX1 or INS specifically, so its findings do not establish the opposite for those two genes; nevertheless, the paper’s stated conclusion runs contrary to the claim attributed to it. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“knockout of miR-375 promotes progressive hyperglycemia in mouse models due to decreased insulin content and progressive loss of β-cell mass ( 32 ).”
What the sources say
- Disputedcites [32] Poy, 2009, miR-375 maintains normal pancreatic alpha- and beta-cell mass, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The Results report hyperglycemia and reduced β-cell mass in miR-375 knockout mice, but the measured mass deficit was 38% at 3 weeks and 31% at 10 weeks, not a progressive loss. The Discussion explicitly attributes their hyperglycemia primarily to an α-cell defect and says the reduction in β-cell mass is unlikely to explain it; plasma insulin was unchanged in these mice. Insulin-deficient diabetes was reported for the separate obese 375/ob model. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Powerful evidence for a genetic component to T2D ( 1 ) has driven extensive efforts to identify genetic variants contributing to risk.”
What the sources say
- Supportedcites [1] Meigs, 2000, Parental transmission of type 2 diabetes: the Framingham Offspring Study, Diabetes source
The paper's Abstract calls type 2 diabetes heritable and says twin concordance, population patterns, and family aggregation support genetic determinants. Its Discussion also considers paternal genetic factors in diabetes risk. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 21 with their cited sources checked
Create a free account to see all 74 claims and every source verdict.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [38]
Experimental — accuracy not yet measured
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336 · cited 1×
“case, these variants explain only a small proportion of total genetic risk (11).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737 · cited 1×
“esis (46), results from a janitorial macrophage infiltration to clear damaged islet b-cells and/or an innate”
BackgroundA pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Self-citationMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“levels that allow proapoptotic IAPP oligomers to form (44) that induce interleukin (IL)-1b release to recruit macrophages and enhance local islet inflammation (45).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“GLP-1based therapies magnify glucose-stimulated insulin secretion, as seen with significantly improved β-cell function in T2D following short-term infusions of GLP-1 (68, 69) and longer-”
Influential
Cited by
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Diabetes mellitus: The epidemic of the century
Kharroubi, A. T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.850 · Cited by 1,229
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Lawlor, N., George, J., Bolisetty, M., Kursawe, R., Sun, L., Sivakamasundari, V., Kycia, I., Robson, P., & Stitzel, M. L. (2017) · Genome Research · doi:10.1101/gr.212720.116 · Cited by 562
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133281 · Cited by 561
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
An Integrated View of Immunometabolism
Lee, Y. S., Wollam, J., & Olefsky, J. M. (2018) · Cell · doi:10.1016/j.cell.2017.12.025 · Cited by 436
“The etiology of T2DM involves both insulin resistance and b-cell dysfunction, and one typically needs both defects in order to develop the full hyperglycemic diabetic state (referred to as the two-hit hypothesis) (Defronzo, 2009; Halban et al., 2014; Olefsky and Glass, 2010).”
BackgroundThe role of macrophages in obesity-associated islet inflammation and β-cell abnormalities
Ying, W., Fu, W., Lee, Y. S., & Olefsky, J. M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0286-3 · Cited by 391
de Mello, V. D., Paananen, J., Lindström, J., Lankinen, M. A., Shi, L., Kuusisto, J., Pihlajamäki, J., Auriola, S., Lehtonen, M., Rolandsson, O., et al. (2017) · Scientific Reports · doi:10.1038/srep46337 · Cited by 379
Chronic tissue inflammation and metabolic disease
Lee, Y. S., & Olefsky, J. (2021) · Genes & Development · doi:10.1101/gad.346312.120 · Cited by 335
“…is referred to other excellent reviews on possible causes of insulin resistance and β-cell dysfunction, independent of chronic tissue inflammation (Halban et al. 2014; DeFronzo et al. 2015; Czech 2017; Newgard 2017; Guilherme et al. 2019; Kahn et al. 2019; Roden and Shulman 2019; Scherer 2019;…”
Backgroundβ Cell dysfunction during progression of metabolic syndrome to type 2 diabetes
Hudish, L. I., Reusch, J. E. B., & Sussel, L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129188 · Cited by 336
Self-citationSchwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329
Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS?
Meza, C. A., La Favor, J. D., Kim, D.-H., & Hickner, R. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153775 · Cited by 323
“As the complete deterioration of β-cell function occurs in advanced T2D [179], the data in animal models of dysregulated hyperglycemia suggest that chronic hyperglycemia may result in excess NOX1-derived superoxide and uncoupled eNOS, thereby attenuating NO production and endothelium-dependent dilation.”
BackgroundPrediabetes and Cardiovascular Disease
Brannick, B., & Dagogo-Jack, S. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.001 · Cited by 293
The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes
Belgardt, B.-F., Ahmed, K., Spranger, M., Latreille, M., Denzler, R., Kondratiuk, N., von Meyenn, F., Villena, F. N., Herrmanns, K., Bosco, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3862 · Cited by 278
Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 275
Maida, C. D., Daidone, M., Pacinella, G., Norrito, R. L., Pinto, A., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042397 · Cited by 220
“All these processes compromise the physiological mobilization of calcium from the endoplasmic reticulum, activate pro-apoptotic signals, determine degradation of the insulin mRNA and promote the release of IL-1β, which triggers inflammation of the pancreatic islets [7].”
BackgroundVitamin D Switches BAF Complexes to Protect β Cells
Wei, Z., Yoshihara, E., He, N., Hah, N., Fan, W., Pinto, A. F. M., Huddy, T., Wang, Y., Ross, B., Estepa, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.013 · Cited by 207
“Initiated by insulin resistance, b cell dysfunction is characterized by defective insulin secretion, endoplasmic reticulum (ER) stress, eventual b cell loss, and disease progression (Ashcroft and Rorsman, 2012; Donath et al., 2013; Halban et al., 2014; Weyer et al., 1999).”
BackgroundDiabetes at the crossroads: relevance of disease classification to pathophysiology and treatment
Leslie, R. D., Palmer, J., Schloot, N. C., & Lernmark, A. (2016) · Diabetologia · doi:10.1007/s00125-015-3789-z · Cited by 204
Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications
Yan, L.-J., Wu, J., Jin, Z., & Zheng, H. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s106087 · Cited by 198
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
Self-citationBeta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Solimena, M., Schulte, A. M., Marselli, L., Ehehalt, F., Richter, D., Kleeberg, M., Mziaut, H., Knoch, K.-P., Parnis, J., Bugliani, M., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4500-3 · Cited by 170
The Beta Cell in Type 2 Diabetes
Christensen, A. A., & Gannon, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1196-4 · Cited by 163
Central nervous system regulation of organismal energy and glucose homeostasis
Myers, M. G., Affinati, A. H., Richardson, N. E., & Schwartz, M. W. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00408-5 · Cited by 175
Dysfunction of Persisting β Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis
Cohrs, C. M., Panzer, J. K., Drotar, D. M., Enos, S. J., Kipke, N., Chen, C., Bozsak, R., Schöniger, E., Ehehalt, F., Distler, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.033 · Cited by 165
Signals in the pancreatic islet microenvironment influence β‐cell proliferation
Aamodt, K. I., & Powers, A. C. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13031 · Cited by 180
Self-citationCohort profile: the German Diabetes Study (GDS)
The GDS Group, Szendroedi, J., Saxena, A., Weber, K. S., Straßburger, K., Herder, C., Burkart, V., Nowotny, B., Icks, A., Kuß, O., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0374-9 · Cited by 166
Insulin granule biogenesis and exocytosis
Omar‐Hmeadi, M., & Idevall‐Hagren, O. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03688-4 · Cited by 143
Islet Amyloid Polypeptide Membrane Interactions: Effects of Membrane Composition
Zhang, X., Clair, J. R. S., London, E., & Raleigh, D. P. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b01016 · Cited by 126
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 100
Navigating the Depths and Avoiding the Shallows of Pancreatic Islet Cell Transcriptomes
Mawla, A. M., & Huising, M. O. (2019) · Diabetes · doi:10.2337/dbi18-0019 · Cited by 123
Briššová, M., Shostak, A., Fligner, C. L., Revetta, F. L., Washington, M. K., Powers, A. C., & Hull, R. L. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415573324 · Cited by 121
“, nutrient excess) to β cell loss and dysfunction has been widely studied (Halban et al. 2014).”
BackgroundSelf-citationMarselli, L., Piron, A., Suleiman, M., Colli, M. L., Yi, X., Khamis, A., Carrat, G., Rutter, G. A., Bugliani, M., Giusti, L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108466 · Cited by 133
New insights into the architecture of the islet of Langerhans: a focused cross-species assessment
Drigo, R. A. E., Ali, Y., Díez, J., Srinivasan, D. K., Berggren, P., & Boehm, B. O. (2015) · Diabetologia · doi:10.1007/s00125-015-3699-0 · Cited by 128
“We refer to a recent review article describing beta cell pathophysiology in type 2 diabetes [115], describing beta cell failure as a central mechanism in both type 1 and type 2 diabetes.”
MethodDang, S., Leng, Y., Wang, Z., Xiao, X., Zhang, X., Wen, T., Gong, H.-Z., Hong, A., & Ma, Y. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.28522 · Cited by 112
Eliasson, L. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.043 · Cited by 107
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Solis‐Herrera, C., Triplitt, C. L., DeFronzo, R. A., & Abdul-Ghani, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01838 · Cited by 114
Diabetes-induced male infertility: potential mechanisms and treatment options
Huang, R., Chen, J., Guo, B., Jiang, C., & Sun, W. (2024) · Molecular Medicine · doi:10.1186/s10020-023-00771-x · Cited by 155
“…may be the result of complex interactions between the environment and different molecular pathways involved in cell biology, including a long-term high-glucose, high-fat diet, oxidative stress, chronic inflammation, and epigenetic disruption and imbalances (Maresch et al. 2019; Halban et al. 2014).”
BackgroundAlarcón, C., Boland, B. B., Uchizono, Y., Moore, P. C., Peterson, B. F., Rajan, S., Rhodes, O. S., Noske, A. B., Haataja, L., Arvan, P. R., et al. (2015) · Diabetes · doi:10.2337/db15-0792 · Cited by 102
“The common dysfunctional ß-cell characteristics in type 2 diabetes include: diminished glucosesensing, increased basal insulin secretion, blunted first phase insulin secretory response to glucose, increased proinsulin to insulin ratios (3; 4), together with a presumed decrease in insulin production (3).”
BackgroundInfluentialSelf-citationThivolet, C. H., Vial, G., Cassel, R., Rieusset, J., & Madec, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182027 · Cited by 103
“Decreased beta cell function and mass predict diabetes onset and progression [1].”
BackgroundTyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Fountas, A., Diamantopoulos, L. N., & Tsatsoulis, A. A. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.003 · Cited by 101
Bacon, S., Kyithar, M. P., Rizvi, S. R., Donnelly, E., McCarthy, A., Burke, M., Colclough, K., Ellard, S., & Byrne, M. M. (2015) · Diabetic Medicine · doi:10.1111/dme.12992 · Cited by 99
Edwards, C., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.007 · Cited by 120
Genetic risk converges on regulatory networks mediating early type 2 diabetes
Walker, J. T., Saunders, D. C., Rai, V., Chen, H., Orchard, P., Dai, C., Pettway, Y. D., Hopkirk, A. L., Reihsmann, C., Tao, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06693-2 · Cited by 93
Self-citationGuan, L.-X., Guan, H., Li, H.-B., Ren, C., Liu, L., Chu, J.-J., & Dai, L. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2339 · Cited by 93
“…exist in the pathogenesis of T2D, the disease is characterized by progressive and inexorable β -cell dysfunction, which subsequently leads to insulin deficiency. β -cell failure is central to the development and progression of T2D, particularly during the later stages of the disease (38).”
Puchałowicz, K., & Rać, M. E. (2020) · Cells · doi:10.3390/cells9081877 · Cited by 97
“In contrast, cell damage leading to a reduction of β-cell mass over time plays a secondary role [13,150,153].”
BackgroundInfluentialmiR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility
Singh, R., Ha, S. E., Wei, L., Jin, B., Zogg, H., Poudrier, S. M., Jorgensen, B. G., Park, C., Ronkon, C. F., Bartlett, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.062 · Cited by 86
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2818 · Cited by 88
Delineating mouse β-cell identity during lifetime and in diabetes with a single cell atlas
Hrovatin, K., Bastidas-Ponce, A., Bakhti, M., Zappia, L., Büttner, M., Salinno, C., Sterr, M., Böttcher, A., Migliorini, A., Lickert, H., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00876-x · Cited by 95
Ansari, P., Khan, J. T., Chowdhury, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2024) · Nutrients · doi:10.3390/nu16213709 · Cited by 131
Tenuta, M. C., Deguin, B., Loizzo, M. R., Dugay, A., Acquaviva, R., Malfa, G. A., Bonesi, M., Bouzidi, C., & Tundis, R. (2020) · Antioxidants · doi:10.3390/antiox9020184 · Cited by 87
“Cell decline play an important role in the development of diabetes mellitu [64].”
BackgroundYang, Y., Li, S., Ren, Q., Qiu, Y., Pan, M., Liu, G., Zheng, R., An, Z., & Li, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02518-2 · Cited by 103
“This phenomenon may be due to prolonged insulin resistance leading to the gradual exhaustion of pancreatic β-cells, resulting in a decrease in insulin secretion levels in the body [58, 59].”
Beta cell dysfunction in diabetes: the islet microenvironment as an unusual suspect
Almaça, J., Caicedo, A., & Landsman, L. (2020) · Diabetologia · doi:10.1007/s00125-020-05186-5 · Cited by 92
The Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 97
Self-citationKaneto, H., Obata, A., Kimura, T., Shimoda, M., Okauchi, S., Shimo, N., Matsuoka, T., & Kaku, K. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12494 · Cited by 82
“Finally, when β-cells are chronically exposed to hyperglycemia, β-cell function gradually deteriorates.(18-23) After exposure to”
BackgroundCytochrome b5 reductases: Redox regulators of cell homeostasis
Hall, R., Yuan, S. S., Wood, K. C., Katona, M., & Straub, A. C. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102654 · Cited by 78
“As such, pancreatic beta cells are unable to maintain insulin production, leading to a reduction in beta cell mass and function (105, 106).”
BackgroundBACH2 inhibition reverses β cell failure in type 2 diabetes models
Son, J., Ding, H., Farb, T. B., Efanov, A. M., Sun, J., Gore, J. L., Syed, S. K., Lei, Z., Wang, Q., Accili, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153876 · Cited by 73
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
Jensen, L., Kupčová, V., Arold, G., Pettersson, J., & Hjerpsted, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13186 · Cited by 84
“components of the pathogenesis of the disease, which is associated with multiple morbidities.(3,4) Glucagon-like peptide-1 (GLP-1) receptor”
BackgroundCanfora, E. E., & Blaak, E. E. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000408 · Cited by 91
Nutrient Metabolism, Subcellular Redox State, and Oxidative Stress in Pancreatic Islets and β-Cells
Roma, L. P., & Jonas, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.10.012 · Cited by 84
Shapira, S. N., Naji, A., Atkinson, M. A., Powers, A. C., & Kaestner, K. H. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.013 · Cited by 86
Self-citationKaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
Li, H., Li, Y., Xiang, L., Zhang, J., Zhu, B., Xiang, L., Dong, J., Liu, M., & Xiang, G. (2017) · Diabetes · doi:10.2337/db17-0086 · Cited by 74
Gupta, D., Jetton, T. L., LaRock, K., Monga, N., Satish, B., Lausier, J., Peshavaria, M., & Leahy, J. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.781047 · Cited by 77
Diabetes mellitus and the skin
Makrantonaki, E., Jiang, D., Hossini, A. M., Nikolakis, G. D., Wlaschek, M., Scharffetter‐Kochanek, K., & Zouboulis, C. C. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9373-0 · Cited by 72
Role of Reactive Oxygen Species in Glucose Metabolism Disorder in Diabetic Pancreatic β-Cells
Mukai, E., Fujimoto, S., & Inagaki, N. (2022) · Biomolecules · doi:10.3390/biom12091228 · Cited by 87
Kim, W. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i1.1 · Cited by 91
Genomics of Islet (Dys)function and Type 2 Diabetes
Lawlor, N. T., Khetan, S., Ucar, D., & Stitzel, M. L. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.01.010 · Cited by 70
“Ultimately, these responses converge on the nucleus and involve re-distribution or covalent modifications of master TFs (MAFB, NKX6-1, PDX1) or stress response factors (FOXO1, ATF4, HIF1alpha) [20,22,53,57,58].”
BackgroundRole of Endoplasmic Reticulum-Mitochondria Communication in Type 2 Diabetes
Rieusset, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-4567-7_13 · Cited by 66
“secretion are involved in altered glucose homeostasis (Halban et al. 2014).”
InfluentialMicroRNAs in islet hormone secretion
Esguerra, J. L. S., Nagao, M., Ofori, J. K., Wendt, A., & Eliasson, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13382 · Cited by 69
Okauchi, S., Shimoda, M., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., Mune, T., Kaku, K., & Kaneto, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.109 · Cited by 64
Decreased STARD10 Expression Is Associated with Defective Insulin Secretion in Humans and Mice
Carrat, G., Hu, M., Nguyen‐Tu, M., CHABOSSEAU, P. L., Gaulton, K. J., van de Bunt, M., Siddiq, A., Falchi, M., Thurner, M., Canouil, M., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.011 · Cited by 65
Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure
Son, J., Du, W. J., Esposito, M., Shariati, K., Ding, H., Kang, Y., & Accili, D. (2023) · Nature Communications · doi:10.1038/s41467-023-36315-4 · Cited by 71
Abdul-Ghani, M., & DeFronzo, R. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
Type 2 Diabetes–Associated Genetic Variants Regulate Chromatin Accessibility in Human Islets
Khetan, S., Kursawe, R., Youn, A., Lawlor, N. T., Jillette, A., Márquez, E. J., Ucar, D., & Stitzel, M. L. (2018) · Diabetes · doi:10.2337/db18-0393 · Cited by 71
“Introduction Type 2 diabetes (T2D) is a complex disease resulting from the combined effects of an individual’s genetic predisposition and environmental exposures (1,2).”
BackgroundAnsari, M. A., Chauhan, W., Shoaib, S., Alyahya, S. A., Ali, M., Ashraf, H., Alomary, M. N., & Al-Suhaimi, E. A. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01369-3 · Cited by 73
Kycia, I., Wolford, B. N., Huyghe, J. R., Fuchsberger, C., Vadlamudi, S., Kursawe, R., Welch, R., Albanus, R. D., Uyar, A., Khetan, S., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.02.020 · Cited by 65
Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes
Dahan, T., Ziv, O., Horwitz, E. P., Zemmour, H., Lavi, J., Swisa, A., Leibowitz, G., Ashcroft, F. M., Veld, P. I. '., Gläser, B., et al. (2016) · Diabetes · doi:10.2337/db16-0641 · Cited by 66
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Beta-Cell Dedifferentiation in Type 2 Diabetes: Concise Review
Efrat, S. (2019) · Stem Cells · doi:10.1002/stem.3059 · Cited by 64
Bearrows, S. C., Bauchle, C. J., Becker, M., Haldeman, J. M., Swaminathan, S., & Stephens, S. B. (2019) · Journal of Cell Science · doi:10.1242/jcs.231373 · Cited by 61
“Compelling evidence highlights the central role of β-cell decompensation in this transition (Halban et al., 2014; Ward et al., 1984).”
BackgroundThe IGFBP3/TMEM219 pathway regulates beta cell homeostasis
D’Addio, F., Maestroni, A., Assi, E., Nasr, M. B., Amabile, G., Usuelli, V., Loretelli, C., Bertuzzi, F., Antonioli, B., Cardarelli, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28360-2 · Cited by 61
Walker, J. T., Haliyur, R., Nelson, H. A., Ishahak, M., Poffenberger, G., Aramandla, R., Reihsmann, C., Luchsinger, J. R., Saunders, D. C., Wang, P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137017 · Cited by 64
Self-citationEpigenetic changes in diabetes
Al-Haddad, R., Karnib, N., Assaad, R. A., Bilen, Y., Emmanuel, N., Ghanem, A., Younes, J., Zibara, V., Stephan, J. S., & Sleiman, S. F. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.04.046 · Cited by 59
Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. R. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000270 · Cited by 63
The role of beta cell heterogeneity in islet function and insulin release
Nasteska, D., & Hodson, D. J. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0011 · Cited by 65
MicroRNA Networks in Pancreatic Islet Cells: Normal Function and Type 2 Diabetes
Eliasson, L., & Esguerra, J. L. S. (2020) · Diabetes · doi:10.2337/dbi19-0016 · Cited by 59
Ciregia, F., Bugliani, M., Ronci, M., Giusti, L., Boldrini, C., Mazzoni, M. R., Mossuto, S., Grano, F., Cnop, M., Marselli, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13908-w · Cited by 60
Type 2 diabetes: Does pancreatic fat really matter?
Guglielmi, V., & Sbraccia, P. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2955 · Cited by 59
Nora, M. C., Morais, T., Almeida, R., Guimarães, M., & Monteiro, M. P. (2017) · Medicine · doi:10.1097/md.0000000000008859 · Cited by 66
Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes
Lee, C.-L., Sheu, W. H., Lee, I., Lin, S., Liang, W., Wang, J., & Li, Y. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.09.001 · Cited by 53
Biondi, G., Marrano, N., Borrelli, A., Rella, M., Palma, G., CALDERONI, I., Siciliano, E., Lops, P., Giorgino, F., & Natalicchio, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105522 · Cited by 69
“During obesity, the nutrient surfeit leads to the development of hyperglycaemia and hyperlipidaemia, which increases the metabolic load and promotes the ectopic storage of lipids in different tissues—including the pancreas [152]—triggering insulin resistance and chronic inflammation [153].”
BackgroundNawrocka, D., Kornicka, K., Szydlarska, J., & Marycz, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3027109 · Cited by 57
Mattisson, I. Y., Björkbacka, H., Wigren, M., Edsfeldt, A., Melander, O., Fredrikson, G. N., Bengtsson, E., Gonçalves, I., Orho‐Melander, M., Engström, G., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.023 · Cited by 55
“Themechanisms responsible for loss of β-cells in diabetes remains a matter of controversy (Cnop et al., 2005;Halban et al., 2014), but several lines of evidence have implicated activation of β-cell apoptosis in response to the metabolic and oxidative stress caused by elevated levels of glucose and…”
BackgroundKhodneva, Y. A., Shalev, A., Frank, S. J., Carson, A. P., & Safford, M. M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.021 · Cited by 55
“[2] Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al.”
BackgroundGarcía-Jacobo, R. E., Uresti‐Rivera, E. E., Portales‐Pérez, D. P., González‐Amaro, R., Lara-Ramirez, E. E., Enciso‐Moreno, J. A., & García-Hernández, M. H. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13147 · Cited by 50
Injury factors alter miRNAs profiles of exosomes derived from islets and circulation
Fu, Q., Jiang, H., Wang, Z., Wang, X., Chen, H., Shen, Z., Xiao, L., Guo, X., & Yang, T. (2018) · Aging · doi:10.18632/aging.101689 · Cited by 53
“Moreover, in vivo and in vitro animal experiments, streptozocin (STZ) is often used to induce diabetes models, which is islet β cell specific damaging agent [12, 13].”
BackgroundKaneto, H., Obata, A., Kimura, T., Shimoda, M., Kinoshita, T., Matsuoka, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063062 · Cited by 49
Metadata
- Authors
- Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
- Affiliations
- University of Geneva (CH)
- University of Chicago (US)
- Wake Forest University (US)
- Albert Einstein College of Medicine (US)
- Lund University (SE)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Columbia University (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Halban, Philippe A.
- Polonsky, Kenneth S.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1751-1758
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4179518
- OpenAlex
- W2142418958
- Semantic Scholar
- b30b808a69da53c538eed4ffb6c8ae812e4bfe16
- Cited by
- 460
- References
- 91
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 30 · 2023: 38 · 2022: 41 · 2021: 37 · 2020: 49 · 2019: 50 · 2018: 46 · 2017: 57 · 2016: 29 · 2015: 30 · 2014: 3
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- University of Pennsylvania
- University of Washington
- University of Exeter
- Vrije Universiteit Amsterdam
- Lunds Universitet
- Novo Nordisk
- Università di Pisa
- Novo Nordisk Fonden (NNF11OC1014546)
- National Institutes of Health (UL1TR000430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082590, P30DK020593, P30DK020595)
- National Center for Advancing Translational Sciences
- Children's Hospital of Pittsburgh
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- beta-cell failure, type 2 diabetes, beta-cell dysfunction, beta-cell mass, genetic susceptibility, diabetes prevention, diabetes treatment, genetic loci, cell therapy, bariatric surgery, circulating factors
- MeSH terms
- Congresses as Topic, Diabetes Mellitus, Type 2, Expert Testimony, Humans, Signal Transduction, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.